Back to search results

Observational Study for Inflammatory Breast Cancer and MRD Testing

This study is collecting information from people with stage III or IV inflammatory breast cancer (IBC). It's looking at how often a specific blood test, called Signatera, shows signs of minimal residual disease (MRD) before surgery. MRD means there are still a few cancer cells left after treatment. You can join if you are 18 or older, have IBC, and have had or plan to have Signatera testing. The study also wants to understand how your quality of life is affected, especially your worries about cancer coming back, if you receive MRD test results. Researchers will follow participants for about one year to see how MRD results relate to treatment and if the cancer returns. The current recruitment status is unclear.

Study design
This is an observational study aiming to enroll 200 participants. It is not testing a new treatment but rather collecting information about existing care.
What's involved
You will be asked to complete a quality-of-life questionnaire, which takes about 10-15 minutes. The study will also collect information from your Signatera blood test results and other clinical data.
Compensation
Not stated in the trial record.
Follow-up
Your quality of life will be measured through study completion, which is an average of one year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06966050

Multi-center MRD Registry for Inflammatory Breast Cancer

Recruiting
Not specifiedAges 18+Observational
M.D. Anderson Cancer Center
~200 participants
Updated 2026-05-20 on ClinicalTrials.gov
What's tested:Quality-of-life Questionnaire

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire
Measured over Through study completion; an average of 1 year

Conditions

Breast Cancer

Explore related trials

Breast Inflammatory CarcinomaCirculating Tumor-Derived DNA Negative

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Sadia Saleem, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Sadia Saleem, MD
[email protected]
281-566-1900
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Female or males ≥18 years of age with the ability to understand and sign a written
Participants who have a clinical diagnosis of stage III or IV inflammatory breast cancer (IBC).
Participants who are planning to have or already completed a minimum of one blood draw for Signatera testing, for which the result and clinical data can be deposited into the study database.
Participants must be within eight months of diagnosis and have not undergone breast surgery for this diagnosis of breast cancer.
Participants must be English-speaking.

What this trial measures

  • European Organization for Research and Treatment of Cancer Core Quality of Life QuestionnaireThrough study completion; an average of 1 year

    European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) Score scale: (1-30 questions to assess the impact of participants quality of life)